Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$274K Sell
4,362
-1,296
-23% -$90.3K 0.01% 1156
2025
Q4
$376K Sell
5,658
-4,956
-47% -$320K 0.01% 941
2025
Q3
$714K Buy
+10,614
New +$840K 0.03% 566
2025
Q2
Sell
-5,251
Closed -$359K 1321
2025
Q1
$359K Buy
5,251
+1,896
+57% +$155K 0.02% 857
2024
Q4
$261K Sell
3,355
-35,801
-91% -$2.65M 0.01% 971
2024
Q3
$2.63M Buy
39,156
+27,824
+246% +$2.28M 0.01% 1372
2024
Q2
$1.28M Buy
+11,332
New +$1.43M ﹤0.01% 1850
2024
Q1
Sell
-3,527
Closed -$443K 3978
2023
Q4
$438K Sell
3,527
-8,983
-72% -$918K ﹤0.01% 2899
2023
Q3
$1.17M Buy
12,510
+5,901
+89% +$665K ﹤0.01% 1895
2023
Q2
$849K Buy
+6,609
New +$799K 0.03% 473

Other funds holding DXCM

GTS Securities's DXCM Position: Q1 2026 in Review

GTS Securities reduced its DexCom (DXCM) stake by 23% in Q1 2026, selling an estimated $90.3K and leaving 4,362 shares worth $274K. The position accounts for 0.01% of the portfolio, ranked #1156.

GTS Securities first reported a position in DXCM in Q2 2023 and has held it in 10 quarters since. The position peaked at $2.63M in Q3 2024. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • GTS Securities held 4,362 shares of DexCom worth $274K as of Q1 2026.
  • GTS Securities sold 1,296 DexCom shares in Q1 2026, an estimated $90.3K.
  • DexCom made up 0.01% of GTS Securities's portfolio in Q1 2026, its #1156 holding.
  • GTS Securities first reported a position in DexCom in Q2 2023 and has held it in 10 quarters since.
  • GTS Securities's DexCom position peaked at $2.63M in Q3 2024.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.